{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:25:30Z","timestamp":1790040330107,"version":"4.0.1"},"reference-count":71,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.25973","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T11:05:59Z","timestamp":1660129559000},"page":"e2225973","source":"Crossref","is-referenced-by-count":43,"title":["Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020"],"prefix":"10.1001","volume":"5","author":[{"given":"Yichen","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Naci","sequence":"additional","affiliation":[{"name":"LSE Health, Department of Health Policy, London School of Economics and Political Science, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita K.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Beijing Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafu","family":"Ji","sequence":"additional","affiliation":[{"name":"Beijing Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwen","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China"},{"name":"International Research Centre for Medicinal Administration, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China"},{"name":"International Research Centre for Medicinal Administration, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"issue":"1","key":"zoi220734r1","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/S1470-2045(14)70380-8","article-title":"Outcomes and endpoints in cancer trials: bridging the divide.","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"zoi220734r5","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals.","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"5","key":"zoi220734r6","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/jnci\/djx232","article-title":"Magnitude of clinical benefit of cancer drugs approved by the US Food and Drug Administration.","volume":"110","author":"Tibau","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"zoi220734r7","doi-asserted-by":"publisher","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"zoi220734r8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015.","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"zoi220734r9","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s10637-021-01117-2","article-title":"The drug lag issue: a 20-year review of China.","volume":"39","author":"Li","year":"2021","journal-title":"Invest New Drugs"},{"issue":"2","key":"zoi220734r10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpt.2019.105.issue-2","article-title":"Challenges and opportunities with oncology drug development in China.","volume":"105","author":"Bajaj","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"zoi220734r12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nbt0513-375","article-title":"China overhauls drug regulation agency.","volume":"31","author":"Jia","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"9","key":"zoi220734r14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrclinonc.2017.10","article-title":"The changing landscape of clinical trial and approval processes in China.","volume":"14","author":"Zhou","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"zoi220734r19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1470-2045(18)30865-9","article-title":"Challenges in anticancer drug R&D in China.","volume":"20","author":"Zhao","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi220734r20","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.drudis.2014.11.005","article-title":"Cancer drug development in China: recent advances and future challenges.","volume":"20","author":"Wu","year":"2015","journal-title":"Drug Discov Today"},{"issue":"11","key":"zoi220734r21","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1016\/S1470-2045(19)30491-7","article-title":"Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review.","volume":"20","author":"Li","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi220734r22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/d41573-021-00080-0","article-title":"Characteristics of expedited programmes for cancer drug approval in China.","volume":"20","author":"Li","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"zoi220734r27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/d41573-020-00195-w","article-title":"Trends in oncology drug innovation in China.","volume":"20","author":"Li","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"zoi220734r33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2021.100151","article-title":"The changing landscape of anti\u2013lung cancer drug clinical trials in mainland China from 2005 to 2020.","volume":"11","author":"Zhong","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"zoi220734r34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology.","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"key":"zoi220734r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.012","article-title":"Strength of validation for surrogate end points used in the US Food and Drug Administration\u2019s approval of oncology drugs.","author":"Kim","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"zoi220734r36","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","article-title":"The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses.","volume":"175","author":"Prasad","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"10","key":"zoi220734r38","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO\u2013Magnitude of Clinical Benefit Scale version 1.1.","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"zoi220734r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2021.100097","article-title":"The changing landscape of anti-lymphoma drug clinical trials in mainland China in the past 15 years (2005-2020): a systematic review.","volume":"8","author":"Chen","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"zoi220734r40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S1470-2045(18)30921-5","article-title":"Dying to survive and cancer care in China.","volume":"20","author":"Lucas","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi220734r41","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1158\/2159-8290.CD-NB2021-0318","article-title":"By the numbers: novel drugs approved by the FDA, 2011-2020.","volume":"11","author":"By the Numbers","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"zoi220734r42","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s00228-020-02850-y","article-title":"Cancer drugs for solid tumors approved by the EMA since 2014: an overview of pivotal clinical trials.","volume":"76","author":"Lasala","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"zoi220734r45","doi-asserted-by":"publisher","DOI":"10.1177\/2381468319855386","article-title":"The value of progression-free survival in metastatic breast cancer: results from a survey of patients and providers.","volume":"4","author":"MacEwan","year":"2019","journal-title":"MDM Policy Pract"},{"key":"zoi220734r46","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2191","article-title":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment.","author":"Dawoud","journal-title":"BMJ"},{"issue":"2","key":"zoi220734r47","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2019.20288","article-title":"FDA approval and regulation of pharmaceuticals, 1983-2018.","volume":"323","author":"Darrow","year":"2020","journal-title":"JAMA"},{"key":"zoi220734r48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2019.100202","article-title":"Is the number of cancer drug approvals a surrogate for regulatory success?","volume":"22","author":"Gyawali","year":"2019","journal-title":"J Cancer Policy"},{"issue":"7","key":"zoi220734r49","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jamainternmed.2019.0583","article-title":"An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate.","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi220734r50","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/cpt.1965","article-title":"Single-arm clinical trials as pivotal evidence for cancer drug approval: a retrospective cohort study of Centralized European Marketing Authorizations between 2010 and 2019.","volume":"108","author":"Tenhunen","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"zoi220734r51","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis.","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"11","key":"zoi220734r52","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","article-title":"A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer.","volume":"123","author":"Cooper","year":"2020","journal-title":"Br J Cancer"},{"issue":"1","key":"zoi220734r53","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1200\/JCO.2007.13.8156","article-title":"Reflections on medical oncology: 25 years of clinical trials\u2014where have we come and where are we going?","volume":"26","author":"Booth","year":"2008","journal-title":"J Clin Oncol"},{"key":"zoi220734r54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.socscimed.2014.12.007","article-title":"Drugs, cancer and end-of-life care: a case study of pharmaceuticalization?","volume":"131","author":"Davis","year":"2015","journal-title":"Soc Sci Med"},{"issue":"2","key":"zoi220734r55","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jamainternmed.2014.6016","article-title":"Patients\u2019 expectations of the benefits and harms of treatments, screening, and tests: a systematic review.","volume":"175","author":"Hoffmann","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"5","key":"zoi220734r56","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1111\/hex.v24.5","article-title":"Information, deliberation, and decisional control preferences for participation in medical decision-making and its influencing factors among Chinese cancer patients.","volume":"24","author":"Xiao","year":"2021","journal-title":"Health Expect"},{"issue":"6","key":"zoi220734r57","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3322\/caac.v69.6","article-title":"Tools to facilitate communication during physician-patient consultations in cancer care: an overview of systematic reviews.","volume":"69","author":"Licqurish","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"zoi220734r58","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1001\/jamainternmed.2021.3505","article-title":"Communication of survival data in US Food and Drug Administration\u2013approved labeling of cancer drugs.","volume":"181","author":"Naci","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"16","key":"zoi220734r59","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2217\/cer-2021-0184","article-title":"Potential policy reforms to strengthen the accelerated approval pathway.","volume":"10","author":"Kaltenboeck","year":"2021","journal-title":"J Comp Eff Res"},{"issue":"5","key":"zoi220734r60","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","article-title":"Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials.","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"12","key":"zoi220734r61","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMp1705800","article-title":"The fate of FDA postapproval studies.","volume":"377","author":"Woloshin","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi220734r62","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jval.2020.10.016","article-title":"Prevalence of immature survival data for anti-cancer drugs presented to the National Institute for Health and Care Excellence and impact on decision making.","volume":"24","author":"Tai","year":"2021","journal-title":"Value Health"},{"issue":"12","key":"zoi220734r63","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1001\/jamainternmed.2021.5989","article-title":"Estimated Medicare spending on cancer drug indications with a confirmed lack of clinical benefit after US Food and Drug Administration accelerated approval.","volume":"181","author":"Shahzad","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"12","key":"zoi220734r64","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1001\/jamainternmed.2021.5983","article-title":"Real-world use of and spending on new oral targeted cancer drugs in the US, 2011-2018.","volume":"181","author":"Fu","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"8","key":"zoi220734r65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003726","article-title":"An open science pathway for drug marketing authorization-registered drug approval.","volume":"18","author":"Naudet","year":"2021","journal-title":"PLoS Med"},{"issue":"5","key":"zoi220734r66","doi-asserted-by":"publisher","first-page":"685","DOI":"10.18553\/jmcp.2021.27.5.685","article-title":"Few new drugs deserve expedited regulatory treatment.","volume":"27","author":"Darrow","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"zoi220734r67","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/s41416-021-01495-7","article-title":"An urgent call to raise the bar in oncology.","volume":"125","author":"Schnog","year":"2021","journal-title":"Br J Cancer"},{"issue":"7","key":"zoi220734r68","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamainternmed.2019.0458","article-title":"An international perspective on drugs for cancer: the best of times, the worst of times.","volume":"179","author":"Lehman","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"11","key":"zoi220734r69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050217","article-title":"Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.","volume":"5","author":"Rising","year":"2008","journal-title":"PLoS Med"},{"issue":"9","key":"zoi220734r70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050191","article-title":"Publication of clinical trials supporting successful new drug applications: a literature analysis.","volume":"5","author":"Lee","year":"2008","journal-title":"PLoS Med"},{"issue":"4","key":"zoi220734r71","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/jamaoncol.2020.6968","article-title":"Updating reports of phase 3 clinical trials for cancer.","volume":"7","author":"Elimova","year":"2021","journal-title":"JAMA Oncol"},{"key":"zoi220734r2","unstructured":"Center for Drug Evaluation, China Food and Drug Administration. Technical guidance for cancer drug clinical trials endpoints. May 15, 2012. Accessed June 30, 2022. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=24d174aa6995cf17e7aa12d6aa0317aa"},{"key":"zoi220734r3","unstructured":"Centre for Drug Evaluation NMPA. Technical guidance for procedure standard of cancer drug clinical trials imaging endpoints (draft). Updated January 15, 2021. Accessed July 31, 2021. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=1463889bfefae69306a17936875a5e66"},{"key":"zoi220734r4","unstructured":"The United States Food and Drug Administration. Clinical trial endpoints for the approval of cancer drugs and biologics: guidance for industry. Accessed July 31, 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-trial-endpoints-approval-cancer-drugs-and-biologics"},{"key":"zoi220734r11","unstructured":"Centre for Drug Evaluation of China Food and Drug Administration. Technical guidance for the structure and content of chemical medicine clinical trial reports. March 18, 2005. Accessed June 30, 2022.  https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=34442f8d2337b1f014f1b6765e0e48f2"},{"key":"zoi220734r13","unstructured":"Center for Drug Evaluation, State Food and Drug Administration. 2017 annual drug evaluation report. March 23, 2018. Accessed July 31, 2021. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/4e5464e8c98de4a48ecfc560ea7f175f"},{"key":"zoi220734r15","unstructured":"State Food and Drug Administration. Deepening the Reform of Drug Review and Approval and Further Encouraging Innovation. February 22, 2013. Accessed June 30, 2022. https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/gzwj\/gzwjyp\/20130222120001551.html"},{"key":"zoi220734r16","unstructured":"Center for Drug Evaluation, China Food and Drug Administration. Technical guideline for cancer drugs clinical trials. May 15, 2005. Accessed June 30, 2022. https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=5b0845c0f79c3a986a4582b85316cda1"},{"key":"zoi220734r17","unstructured":"Center for Drug Evaluation, China Food and Drug Administration. Technical guideline for the collection of cancer drug clinical data for registration. May 15, 2005. Accessed June 30, 2022.  https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=900d075abb7f7b3a9b2a43a6f6077512"},{"key":"zoi220734r18","unstructured":"Center for Drug Evaluation, China Food and Drug Administration. Technical guideline for adding new indications to authorised cancer drugs. May 15, 2005. Accessed June 30, 2022.  https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=495b1b183d607484e17d770dd42a0ca2"},{"key":"zoi220734r23","unstructured":"Centre for Drug Evaluation NMPA. Launched drug information. July 17, 2016. Accessed June 30, 2022. https:\/\/www.cde.org.cn\/"},{"key":"zoi220734r24","unstructured":"Center for Drug Evaluation NMPA. List of launched drugs in China. December 29, 2017. Accessed June 30, 2022. https:\/\/www.cde.org.cn\/hymlj\/index"},{"key":"zoi220734r25","unstructured":"Beijing Cancer Hospital. Home page. Accessed July 31, 2021. https:\/\/www.bjcancer.org\/html\/index.html"},{"key":"zoi220734r26","unstructured":"PharmaCube. NextPharma new drug platform. Accessed July 31, 2021. https:\/\/db.pharmcube.com\/database\/drugde\/main"},{"key":"zoi220734r28","unstructured":"National Medical Products Administration. National Drug Code Standard Code. Updated December 31, 2021. Accessed July 31, 2021. https:\/\/www.nmpa.gov.cn\/zwfw\/zwfwzxfw\/zxfwsjxz\/20210108152327108.html"},{"key":"zoi220734r29","unstructured":"The United States Food and Drug Administration. Drugs@FDA: FDA-approved drugs. Accessed July 31, 2021. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm"},{"key":"zoi220734r30","unstructured":"European Medicines Agency. Medicines. Accessed July 31, 2021. https:\/\/www.ema.europa.eu\/en\/medicines"},{"key":"zoi220734r31","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: supportive care. Accessed July 31, 2021. https:\/\/www.nccn.org\/guidelines\/category_3"},{"key":"zoi220734r32","unstructured":"National Medical Products Administration. Notice on printing and distributing the specifications and rules for on chemical medicine and biological products. May 10, 2006. Accessed July 31, 2021. https:\/\/www.nmpa.gov.cn\/xxgk\/fgwj\/gzwj\/gzwjyp\/20060510010101566.html"},{"key":"zoi220734r37","unstructured":"European Society for Medical Oncology. ESMO\u2013Magnitude of Clinical Benefit Scale scorecards. Accessed July 31, 2021. https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-scorecards"},{"key":"zoi220734r43","unstructured":"Center for Drug Evaluation, State Drug. Circular of the Center for Drug Evaluation of the State Food and Drug Administration on issuing the guidelines for the statistical design of clinical trials of antineoplastic drugs (Trial). December 31, 2020. Accessed July 31, 2020. https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/b8a33e6df753b13e091b83b8d5a412f8"},{"key":"zoi220734r44","unstructured":"European Medicines Agency. Evaluation of anticancer medicinal products in man\u2014revision 6. November 16, 2020. Accessed July 31, 2021. https:\/\/www.ema.europa.eu\/en\/evaluation-anticancer-medicinal-products-man"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2794990\/zhang_2022_oi_220734_1659120989.86489.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T11:06:08Z","timestamp":1660129568000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2794990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":71,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.25973","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]}}}